Citations

Mayo Clinic

Showing 10 of 108599 citations.

Role of Nrf2 Signaling in the Regulation of Vascular BK Channel β1 Subunit Expression and BK Channel Function in High-Fat Diet–Induced Diabetic Mice
Lü, Tong , Sun, Xiaojing , Chai, Qiang , Wang, Xiao-Li, Lee, Hon-Chi, Li, Yong , Chai, Qiang, Wang, Xiao-Li, Lu, Tong

Diabetes | May 3, 2017 | Volume: 66 | Issue: 10 | Pages: 2681-2690

10.2337/db17-0181 | PMID 28465407 Get It

The large conductance Ca2+-activated K+ (BK) channel β1-subunit (BK-β1) is a key modulator of BK channel electrophysiology and the downregulation of BK-β1 protein expression in vascular smooth muscle cells (SMCs) underlies diabetic vascular dysfunction. In this study, we hypothesized that the nuclear factor erythroid-2–related factor 2 (Nrf2) signaling pathway plays a significant role in the regulation of coronary BK channel function and vasodilation in high-fat diet (HFD)–induced obese/diabetic mice. We found that the protein expressions of BK-β1 and Nrf2 were markedly downregulated, whereas those of the nuclear factor-κB (NF-κB) and the muscle ring finger protein 1 (MuRF1 [a ubiquitin E3 ligase for BK-β1]) were significantly upregulated in HFD mouse arteries. Adenoviral expression of Nrf2 suppressed the protein expressions of NF-κB and MuRF1 but enhanced BK-β1 mRNA and protein expressions in cultured coronary SMCs. Knockdown of Nrf2 resulted in reciprocal changes of these proteins. Patch-clamp studies showed that coronary BK-β1–mediated channel activation was diminished in HFD mice. Importantly, the activation of Nrf2 by dimethyl fumarate significantly reduced the body weight and blood glucose levels of HFD mice, enhanced BK-β1 transcription, and attenuated MuRF1-dependent BK-β1 protein degradation, which in turn restored coronary BK channel function and BK channel–mediated coronary vasodilation in HFD mice. Hence, Nrf2 is a novel regulator of BK channel function with therapeutic implications in diabetic vasculopathy.
A survey evaluating surgeons’ peri-operative usage of acetyl-salicylic acid (ASA) and their willingness to enroll their patients in a perioperative ASA randomized controlled trial
Hiralal, Rajesh, Bhandari, Mohit , Cook, Deborah, Berwanger, Otávio , Beer, Justin de , Cinà, Claudio S. , Marcaccio, Michael , Paul, James , Whiteacre, Laura, Guyatt, Gordon , Cook, Deborah, Buckley, Norman , Villar, Juan Carlos , Montori, Víctor M. , Devereaux, P.J.

Clinical and Investigative Medicine | May 2, 2017 | Volume: 33 | Issue: 6 | Pages: E375-E383

10.25011/cim.v33i6.14588 | PMID 21134339 Get It

Purpose Major cardiovascular complications associated with noncardiac surgery represent a substantial population health problem for which there are no established efficacious and safe prophylactic interventions. Acetyl-salicylic acid (ASA) represents a promising intervention. The objective of this study was to determine surgeons' perioperative usage of ASA, and if they would enrol their patients in a perioperative ASA randomized controlled trial (RCT). Methods Cross-sectional survey of all practicing Canadian general, orthopedic, and vascular surgeons. Our mailed, self-administered survey asked surgeons to consider only their patients who were at risk of a major perioperative cardiovascular complication. Results The response rate was 906/1854 (49%). For patients taking ASA chronically, there was marked variability regarding ASA continuation prior to surgery amongst the general and orthopedic surgeons, whereas 76% of vascular surgeons continued ASA in 81-100% of their patients. For patients not taking ASA chronically, approaches to starting ASA prior to surgery were variable amongst the vascular surgeons, whereas 70% of general and 82% of orthopaedic surgeons did not start ASA. For patients taking ASA chronically, 73% of general surgeons, 70% of orthopaedic surgeons, and 36% of vascular surgeons would allow at least 40% of their patients to participate in a perioperative RCT comparing stopping versus continuing ASA. For patients not taking ASA chronically, most general (76%), orthopaedic (67%), and vascular (51%) surgeons would allow at least 40% of their patients to participate in a perioperative RCT comparing starting ASA versus placebo. Conclusion This national survey demonstrates that perioperative ASA usage as reported by surgeons is variable, identifying the need for, and community interest in, a large perioperative ASA trial.
Development of diabetes does not alter behavioral and molecular circadian rhythms in a transgenic rat model of type 2 diabetes mellitus
Qian, Jingyi , Thomas, Anthony P., Schroeder, Analyne , Rakshit, Kuntol, Colwell, Christopher S. , Matveyenko, Aleksey V.

American Journal of Physiology-Endocrinology and Metabolism | May 2, 2017 | Volume: 313 | Issue: 2 | Pages: E213-E221

10.1152/ajpendo.00406.2016 | PMID 28465284 Get It

Metabolic state and circadian clock function exhibit a complex bidirectional relationship. Circadian disruption increases propensity for metabolic dysfunction, whereas common metabolic disorders such as obesity and type 2 diabetes (T2DM) are associated with impaired circadian rhythms. Specifically, alterations in glucose availability and glucose metabolism have been shown to modulate clock gene expression and function in vitro; however, to date, it is unknown whether development of diabetes imparts deleterious effects on the suprachiasmatic nucleus (SCN) circadian clock and SCN-driven outputs in vivo. To address this question, we undertook studies in aged diabetic rats transgenic for human islet amyloid polypeptide, an established nonobese model of T2DM (HIP rat), which develops metabolic defects closely recapitulating those present in patients with T2DM. HIP rats were also cross-bred with a clock gene reporter rat model (Per1:luciferase transgenic rat) to permit assessment of the SCN and the peripheral molecular clock function ex vivo. Utilizing these animal models, we examined effects of diabetes on 1) behavioral circadian rhythms, 2) photic entrainment of circadian activity, 3) SCN and peripheral tissue molecular clock function, and 4) melatonin secretion. We report that circadian activity, light-induced entrainment, molecular clockwork, as well as melatonin secretion are preserved in the HIP rat model of T2DM. These results suggest that despite the well-characterized ability of glucose to modulate circadian clock gene expression acutely in vitro, SCN clock function and key behavioral and physiological outputs appear to be preserved under chronic diabetic conditions characteristic of nonobese T2DM.
Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors
Burris, Howard A. , Infante, Jeffrey R., Ansell, Stephen M. , Weiss, Geoffrey R. , Villalobos, Víctor M. , Šikić, Branimir I. , Northfelt, Donald W. , Carson, William E. , Hawthorne, Thomas, Davis, Thomas A., Yellin, Michael , Keler, Tibor , Infante, Jon , Nemunaitis, John J, Hawthorne, Thomas R, Yellin, Michael J, Bullock, Timothy, Nemunaitis, John , Taylor, Matthew H. , Bullock, Timothy N J , Carson, William E , Infante, Jon

Journal of Clinical Oncology | May 2, 2017 | Volume: 35 | Issue: 18 | Pages: 2028-2036

10.1200/jco.2016.70.1508 | PMID 28463630 Get It

Purpose CD27, a costimulatory molecule on T cells, induces intracellular signals that mediate cellular activation, proliferation, effector function, and cell survival upon binding to its ligand, CD70. Varlilumab is a novel, first-in-class, agonist CD27 antibody that stimulates the CD27 pathway, which results in T-cell activation and antitumor activity in tumor models. This first-in-human, dose-escalation and expansion study evaluated the safety, pharmacology, and activity of varlilumab in patients with advanced solid tumors. Methods In a 3 + 3 dose-escalation design (n = 25), patients received a single dose of varlilumab (0.1, 0.3, 1.0, 3.0, or 10 mg/kg intravenously) with a 28-day observation, followed by up to five multidose cycles (one dose per week for 4 weeks), depending on tumor response. Expansion cohorts were initiated at 3.0 mg/kg in patients with melanoma (n = 16) and renal cell carcinoma (RCC; n = 15). Primary objectives were to assess the safety and the maximum tolerated and optimal biologic doses of varlilumab. Secondary objectives were to evaluate the pharmacokinetics, pharmacodynamics, and clinical antitumor activity of varlilumab. Results Exposure to varlilumab was linear and dose proportional across dose groups. Only one patient experienced a dose-limiting toxicity—grade 3 transient asymptomatic hyponatremia at the 1.0-mg/kg dose level. Treatment-related adverse events were generally grade 1 or 2 in severity. Evidence of biologic activity consistent with CD27 stimulation—chemokine induction, T-cell stimulation, regulatory T cell depletion—was observed at all dose levels. A patient with metastatic RCC experienced a partial response (78% shrinkage, progression-free survival > 2.3 years). Eight patients experienced stable disease > 3 months, including a patient with metastatic RCC with progression-free survival of > 3.9 years. Conclusion Dose escalation of varlilumab to 10 mg/kg was well tolerated without identification of a maximum tolerated dose. Varlilumab was biologically and clinically active.
Imaging of Abdominal and Pelvic Manifestations of Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplant
Lubner, Meghan G. , Menias, Christine O. , Agrons, Michelle M. , Alhalabi, Kinan , Katabathina, Venkata S. , Elsayes, Khaled M. , Pickhardt, Perry J.

American Journal of Roentgenology | May 2, 2017 | Volume: 209 | Issue: 1 | Pages: 33-45

10.2214/ajr.17.17866 | PMID 28463600 Get It

Decline in prevalence and risk of helicobacter pylori in kidney transplant recipients: A systematic review and meta‐analysis
Cheungpasitporn, Wisit , Wijarnpreecha, Karn , Mitema, Donald, Nissaisorakarn, Pitchaphon , Podboy, Alexander , Kittanamongkolchai, Wonngarm , Sakhuja, Ankit , Erickson, Stephen B., Mitema, Donald G, Mao, Michael A. , Thongprayoon, Charat , Cheungpasitporn, Wisit , Nissaisorakarn, Pitchaphon , Wijarnpreecha, Karn

Journal of Evidence-Based Medicine | May 2, 2017 | Volume: 10 | Issue: 3 | Pages: 171-176

10.1111/jebm.12252 | PMID 28464553 Get It

AbstractObjectiveThe study's aims were (1) to investigate the prevalence and (2) to assess the risk of Helicobacter pylori (H. pylori) infection in kidney transplant recipients.MethodsA comprehensive literature search was performed from inception until September 2016. Studies that reported prevalence, relative risks, odd ratios, or hazard ratios of H. pylori among kidney transplant recipients were included. Pooled risk ratios and 95% CI were calculated using a random‐effect model.ResultsEleven observational studies with 2545 kidney transplant recipients were enrolled. Between year 1990 and 2000, the estimated prevalence of H. pylori among people with kidney transplant was 50% (95% CI: 31% to 68%), with a prevalence of 46% (95% CI: 23% to 70%) in high‐income countries and 55% (95% CI: 22% to 86%) in middle‐income countries, respectively. From year 2000 to 2016, the estimated prevalence of H. pylori among people with kidney transplant was 35% (95% CI: 26% to 45%), with a prevalence of 28% (95% CI: 19% to 37%) in high‐income countries and 45% (95% CI: 38% to 51%) in middle‐income countries. Data regarding prevalence of H. pylori infection in low‐income countries were limited. The pooled RR of H. pylori in kidney transplant recipients was 0.57 (95% CI: 0.33 to 1.00) when compared to people with non‐transplant.ConclusionsThere has been a decline in prevalence of H. pylori in kidney transplant recipients with the overall estimated prevalence of H. pylori in kidney transplant recipients of 35%, particularly in both high‐income and middle‐income countries. Also, our meta‐analysis demonstrates a potential decreased risk of H. pylori infection in kidney transplant recipients compared with non‐transplant populations.
Review article: maximising quality of life while aspiring for quantity of life in end‐stage liver disease
Bhanji, Rahima A. , Carey, Elizabeth J. , Watt, Kymberly D. , Watt, K D

Alimentary Pharmacology & Therapeutics | May 2, 2017 | Volume: 46 | Issue: 1 | Pages: 16-25

10.1111/apt.14078 | PMID 28464346 Get It

SummaryBackgroundWith recent advances in the management of chronic liver disease and its complications, the long‐term survival in cirrhosis has improved. Therefore, the number of individuals who will spend a significant proportion of their life with end‐stage liver disease (ESLD) may continue to rise. Thus, more attention to quality of life (QOL) and its integration with traditional clinical endpoints is needed.AimsRecently, there have been many studies looking at treatment outcomes and their impact on the QOL in patients with ESLD. The aim of this review was to summarise and compare the insights gained from these intervention studies and to make concise recommendations to further promote and improve QOL in this patient population.MethodsA literature search was conducted using PubMed and Web of Science. Search terms “Quality of life” “Cirrhosis” and “end‐stage liver disease” were used as MeSH terms or searched in the title of the article.ResultsThese studies uniformly show significant improvement in health‐related QOL (HRQOL) with management of malnutrition, hepatic encephalopathy and ascites. Thus, early recognition and management of these complications are keys to better serve our patients. Early involvement of palliative care also leads to improved quality of end‐of‐life care.ConclusionsComplications of cirrhosis including malnutrition, encephalopathy, ascites and variceal bleeding lead to a decrease in HRQOL. Assessment of HRQOL has an important implication for the patient. The findings of this review illuminate the importance of using consistent tools to accurately assess QOL in patients with ESLD.
Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials
Brosnahan, Godela , Rahbari-Oskoui, Frederic F. , Patterson, Charity G. , Bae, Kyongtae T. , Schrier, Robert W., Braun, William E. , Chapman, Arlene B., Flessner, Michael F., Harris, Peter C. , Steinman, Theodore I., Torres, Vicente E. , Abebe, Kaleab Z , Perrone, Ronald D. , Harris, Peter C , Torres, Vicente E , Rahbari-Oskoui, Frederic F

Current Hypertension Reviews | May 2, 2017 | Volume: 13 | Issue: 2 | Pages: No page available

10.2174/1573402113666170427142815 | PMID 28460625 Get It

Risk Factors and Time to Recurrent Ipsilateral and Contralateral Patellar Dislocations
Christensen, Tyson C. , Sanders, Thomas L. , Pareek, Ayoosh , Mohan, Rohith , Dahm, Diane L., Krych, Aaron J. , Krych, Aaron J

The American Journal of Sports Medicine | May 2, 2017 | Volume: 45 | Issue: 9 | Pages: 2105-2110

10.1177/0363546517704178 | PMID 28463535 Get It

Background: Previous studies have reported variable rates of recurrent lateral patellar instability mainly because of limited cohort sizes. In addition, there is currently a lack of information on contralateral patellar instability. Purpose: To evaluate the rate of recurrent ipsilateral patellar dislocations and contralateral patellar dislocations after a first-time lateral patellar dislocation. Additionally, risk factors associated with recurrent dislocations (ipsilateral or contralateral) and time to recurrence were investigated. Study Design: Cohort study; Level of evidence, 3. Methods: This population-based study included 584 patients with a first-time lateral patellar dislocation occurring between 1990 and 2010. A retrospective review was conducted to gather information about the injury, subsequent dislocations (ipsilateral or contralateral), and structural characteristics including trochlear dysplasia, patella alta, and tibial tubercle to trochlear groove (TT-TG) distance. Risk factors were assessed to delineate associations with subsequent dislocations and time to recurrence. Results: At a mean follow-up of 12.4 years, 173 patients had ipsilateral recurrence, and 25 patients had a subsequent contralateral dislocation. At 20 years, the cumulative incidence of ipsilateral recurrence was 36.0%, while the cumulative incidence of contralateral dislocations was 5.4%. Trochlear dysplasia (odds ratio [OR], 18.1), patella alta (OR, 10.4), age <18 years at the time of the first dislocation (OR, 2.4), elevated TT-TG distance (OR, 2.1), and female sex (OR, 1.5) were associated with recurrent ipsilateral dislocations. Time to recurrence was significantly decreased in patients with trochlear dysplasia (23.0 months earlier time to recurrence; P < .001), elevated TT-TG distance (18.5 months; P < .001), patella alta (16.4 months; P = .001), and age <18 years at the time of the first dislocation (15.4 months; P < .001). Risk factors for subsequent contralateral dislocations included patella alta and trochlear dysplasia. Conclusion: At 20 years after a first-time lateral patellar dislocation, the cumulative incidence of recurrent ipsilateral patellar dislocations was 36.0%, compared with 5.4% for contralateral dislocations. Trochlear dysplasia, elevated TT-TG distance, patella alta, age <18 years at the time of the first dislocation, and female sex were associated with ipsilateral recurrence. Trochlear dysplasia, elevated TT-TG distance, patella alta, and age <18 years at the time of the first dislocation were predictive of a statistically significant decrease in time to recurrence.
Biopsy of CT-Occult Bone Lesions Using Anatomic Landmarks for CT Guidance
Hillen, Travis J. , Talbert, Robert J., Friedman, Michael , Long, Jeremiah R. , Jennings, Jack W. , Wessell, Daniel E. , Baker, Jonathan C.

American Journal of Roentgenology | May 2, 2017 | Volume: 209 | Issue: 1 | Pages: 214-221

10.2214/ajr.16.17468 | PMID 28463540 Get It